Reimbursed Care Access in Åland Islands

Currently classified as a strictly controlled substance under Finnish national drug scheduling (Narcotics Act) with no authorised general medical use outside of approved clinical research. Clinical access is limited to authorised trials and research licences; routine medical prescription or reimbursement is not permitted under existing law. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Access in Åland follows Finnish national law and is restricted to licensed clinical trials or authorised research projects. #

Esketamine (Spravato) is authorised for treatment-resistant major depressive disorder in the European Union via the EMA assessment and is subject to special prescription and supervised administration requirements. The EMA product page notes EU authorisation and the requirement that Spravato be administered under direct healthcare professional supervision due to risk of misuse and adverse effects. #

In Finland (and therefore in Åland for controlled-medicine regulatory purposes), medicines are reimbursed through the national reimbursement system administered by Kela and decisions on whether a specific medicine is reimbursable (and at which rate) are handled via the Pharmaceuticals Pricing Board (HILA) and Kela processes; reimbursement generally requires that the medicine have a confirmed reimbursement status or that an individual special permit/prior authorisation is granted. Patients receiving specialised medicines in private settings may also require prior authorisation or local health‑service arrangements for coverage; Kela publishes the rules and processes for medicine and private care reimbursement and prior authorisation workflows. Practically, esketamine/Spravato is available only in specialist clinics that meet the product’s supervised-administration requirements and reimbursement/coverage in Finland can require prior authorisation or be handled as a non‑standard reimbursable medicine depending on HILA/Kela decisions. # #

Regional note: Åland has its own health administration for service delivery, but criminal/drug law and national pharmaceutical reimbursement law remain governed by Finnish national law (see Finnish Narcotics Act and Åland governmental responsibilities), so availability/reimbursement of Spravato in Åland will follow Finnish regulatory/reimbursement routes while service delivery and commissioning decisions are managed by Åland’s health authorities. # #

Ketamine is a legally authorised pharmaceutical (used widely as an anaesthetic) and is used off‑label in many countries, including Finland, for acute suicidality and treatment‑resistant depression in specialist settings; such use is typically provided in hospital or specialised outpatient clinics rather than as a reimbursed, routine outpatient prescription. In Finland, ketamine infusions and S‑ketamine formulations have been used in specialised care and in clinical trials, and treatment with ketamine for TRD has been provided in specialised healthcare settings (public hospital specialist care or private specialist clinics) rather than via a broad, standard reimbursed outpatient prescription pathway. This constitutes off‑label medical use rather than an approved reimbursable indication in general practice. # #

Reimbursement/coverage considerations: because ketamine use for depression is off‑label, reimbursement through Kela depends on whether the treatment is provided as part of publicly commissioned specialised healthcare (in which case it may be covered by the public provider) or as private care (where partial Kela reimbursement for private specialist services may be possible subject to Kela rules and prior authorisation). Where ketamine is used in clinical trials or hospital inpatient settings, costs are typically borne by the study sponsor or the public provider. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Routine medical prescription or reimbursement is not available. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. Access is limited to authorised research settings. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. There is no recognised reimbursable medical framework in Finland/Åland for ibogaine treatment. #

Contains DMT and is therefore treated under Finnish narcotics law as an illegal controlled substance in non‑research contexts; no authorised medical or reimbursed use outside approved clinical research. Possession, import or distribution outside authorised research/medical frameworks may incur criminal penalties under the Finnish Narcotics Act. #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; routine medical prescription or reimbursement is not permitted. #

Currently classified as a strictly controlled substance (or covered under consumer‑market / new psychoactive substance bans) under Finnish national law and related decrees, with no authorised medical use outside of approved clinical research. Use outside authorised research is criminalised. #